Mega Lifesciences PCL (BKK:MEGA)

Market Cap	34.44B +15.3%
Revenue (ttm)	14.19B -10.6%
Net Income	1.97B +6.9%
EPS	2.26 +6.8%
Shares Out	871.87M
PE Ratio	17.44
Forward PE	15.75
Dividend	1.60 (4.05%)
Ex-Dividend Date	Aug 27, 2025

Volume	1,856,406
Average Volume	1,737,323
Open	39.00
Previous Close	39.50
Day's Range	38.50 - 39.50
52-Week Range	24.30 - 40.00
Beta	0.27
RSI	69.50
Earnings Date	Feb 24, 2026

About Mega Lifesciences PCL

Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provides various medicines for allergies; blood circulation and memory; bone and joint; liver and digestive; diabetics; eyes, heart, and skin care; pain, sl...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1982
• Employees: 900
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: MEGA

Financial Performance

In 2024, Mega Lifesciences PCL's revenue was 15.39 billion, a decrease of -2.10% compared to the previous year's 15.72 billion. Earnings were 2.01 billion, an increase of 0.99%.